Summary of Study ST002943

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001830. The data can be accessed directly via it's Project DOI: 10.21228/M85H91 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)
Study IDST002943
Study TitleTargeted bile acid analysis for the XMaS trial.
Study SummaryThe Xanthohumol microbiome and signature (XMaS) study in healthy adults was a phase I, triple-masked, placebo-controlled clinical trial in healthy adults investigating effects of a natural product supplement of gut microbiome composition and metabolism. Xanthohumol, a flavonoid from the hops plant or placebo was administered to 27 healthy adults daily for eight weeks. Fecal, plasma, and 24-hr urine collections were obtained from participants at baseline and 2-week intervals. The main objective of this study was to quantify fecal bile acids from participants from the XMaS study.
Institute
Oregon State University
Last NameJamieson
First NamePaige
Address307 LINUS PAULING SCIENCE CTR
Emailjamiesop@oregonstate.edu
Phone5417379804
Submit Date2023-10-23
Analysis Type DetailLC-MS
Release Date2024-01-01
Release Version1
Paige Jamieson Paige Jamieson
https://dx.doi.org/10.21228/M85H91
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR001830
Project DOI:doi: 10.21228/M85H91
Project Title:Targeted analyses of microbial metabolism for the XMaS clinical trial
Project Summary:The Xanthohumol microbiome and signature (XMaS) study in healthy adults was a phase I, triple-masked, placebo-controlled clinical trial in healthy adults investigating effects of a natural product supplement of gut microbiome composition and metabolism. Xanthohumol, a flavonoid from the hops plant or placebo was administered to 27 healthy adults daily for eight weeks. Fecal, plasma, and 24-hr urine collections were obtained from participants at baseline and 2-week intervals. The main objective was to examine clinical safety and subjective tolerability of xanthohumol compared to placebo. Additional aims were to monitor biomarkers of inflammation, gut permeability, bile acid metabolism, short-chain fatty acids, and metabolism of xanthohumol.
Institute:Oregon State University
Last Name:Jamieson
First Name:Paige
Address:307 LINUS PAULING SCIENCE CTR
Email:jamiesop@oregonstate.edu
Phone:5417379804

Subject:

Subject ID:SU003056
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id time_weeks intervention
SA320240s106-10 control
SA320241s112-10 control
SA320242s117-10 control
SA320243s122-10 control
SA320244s104-10 control
SA320245s126-10 control
SA320246s109-10 control
SA320247s110-10 control
SA320248s107-10 control
SA320249s114-10 control
SA320250s121-10 control
SA320251s118-10 control
SA320252s119-10 control
SA320253s101-10 treated
SA320254s111-10 treated
SA320255s131-10 treated
SA320256s102-10 treated
SA320257s123-10 treated
SA320258s124-10 treated
SA320259s116-10 treated
SA320260s130-10 treated
SA320261s127-10 treated
SA320262s115-10 treated
SA320263s103-10 treated
SA320264s113-10 treated
SA320265s129-10 treated
SA320266s105-10 treated
SA320267s121-22 control
SA320268s114-22 control
SA320269s117-22 control
SA320270s110-22 control
SA320271s119-22 control
SA320272s118-22 control
SA320273s112-22 control
SA320274s122-22 control
SA320275s109-22 control
SA320276s104-22 control
SA320277s106-22 control
SA320278s107-22 control
SA320279s126-22 control
SA320280s113-22 treated
SA320281s124-22 treated
SA320282s127-22 treated
SA320283s131-22 treated
SA320284s105-22 treated
SA320285s116-22 treated
SA320286s103-22 treated
SA320287s101-22 treated
SA320288s123-22 treated
SA320289s130-22 treated
SA320290s102-22 treated
SA320291s129-22 treated
SA320292s111-22 treated
SA320293s115-22 treated
SA320294s118-34 control
SA320295s119-34 control
SA320296s114-34 control
SA320297s112-34 control
SA320298s110-34 control
SA320299s107-34 control
SA320300s117-34 control
SA320301s122-34 control
SA320302s106-34 control
SA320303s109-34 control
SA320304s104-34 control
SA320305s121-34 control
SA320306s126-34 control
SA320307s131-34 treated
SA320308s127-34 treated
SA320309s123-34 treated
SA320310s124-34 treated
SA320311s129-34 treated
SA320312s130-34 treated
SA320313s115-34 treated
SA320314s113-34 treated
SA320315s111-34 treated
SA320316s105-34 treated
SA320317s103-34 treated
SA320318s101-34 treated
SA320319s116-34 treated
SA320320s102-34 treated
SA320321s112-46 control
SA320322s121-46 control
SA320323s122-46 control
SA320324s126-46 control
SA320325s104-46 control
SA320326s106-46 control
SA320327s107-46 control
SA320328s110-46 control
SA320329s109-46 control
SA320330s118-46 control
SA320331s117-46 control
SA320332s114-46 control
SA320333s119-46 control
SA320334s127-46 treated
SA320335s103-46 treated
SA320336s129-46 treated
SA320337s124-46 treated
SA320338s131-46 treated
SA320339s105-46 treated
Showing page 1 of 2     Results:    1  2  Next     Showing results 1 to 100 of 135

Collection:

Collection ID:CO003049
Collection Summary:Fecal samples were collected longitudinally at 2-week intervals during the 8-week study. Samples were kept on ice immediately after collection and snap-frozen, then stored in -80 freezers until processing.
Sample Type:Feces

Treatment:

Treatment ID:TR003065
Treatment Summary:Participants were randomly allocated to intervention arms to receive either 24 mg or a rice protein placebo capsule daily for 8 weeks. Clinic check-in and sample collections occurred at baseline and 2-week intervals until study close-out (week 8).

Sample Preparation:

Sampleprep ID:SP003062
Sampleprep Summary:Fecal samples were dried using vacuum desiccator and 70% methanol:water (1:4 w/v) was added for fecal homogenate. Samples were centrifuged and supernatant was collected. 10 uL of fecal supernatant, 10 uL of cholic acid-D4 internal standard (1 ug/mL in ethanol) and 80 uL of 50% methanol:water were mixed and added to a autosampler vial.

Combined analysis:

Analysis ID AN004828
Analysis type MS
Chromatography type Reversed phase
Chromatography system Shimadzu 20AD
Column Waters ACQUITY UPLC CSH C18 (100 x 2.1mm,1.7um)
MS Type ESI
MS instrument type Triple quadrupole
MS instrument name ABI Sciex 4000 QTrap
Ion Mode NEGATIVE
Units ng/g

Chromatography:

Chromatography ID:CH003648
Instrument Name:Shimadzu 20AD
Column Name:Waters ACQUITY UPLC CSH C18 (100 x 2.1mm,1.7um)
Column Temperature:40
Flow Gradient:0 to 1 min, 35% B; 10 min, 60% B; 10.5 min, 99% B; 13 min, 99% B; 13.5 to 17 min, 35% B
Flow Rate:0.25 mL/min
Solvent A:water with 0.1% formic acid (v/v)
Solvent B:acetonitrile with 0.1% formic acid (v/v)
Chromatography Type:Reversed phase

MS:

MS ID:MS004574
Analysis ID:AN004828
Instrument Name:ABI Sciex 4000 QTrap
Instrument Type:Triple quadrupole
MS Type:ESI
MS Comments:Metabolites were confirmed by matching m/z values, retention times and product ions of SRM transitions with those of reference standards
Ion Mode:NEGATIVE
  logo